Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Gene therapy maker bluebird bio on Friday agreed to be taken private by Carlyle and SK Capital Partners at a discount, ending ...

Penny and Fritz Brandau, members of the Black River Audubon Society and the Ohio Bluebird Society, will give a presentation about Eastern Bluebirds for the Brownhelm Historical Association on ...

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Bluebird Bio announced it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed ...

The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...

JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement ...

Lafayette Consolidated Government’s Traffic, Roads, and Bridges Department has planned a traffic signal outage at Camellia ...